It is extremely satisfying when we are able to help our clients impact the world in a positive way through the Health Economics and Outcomes Research (HEOR) space. When we started Anlitiks, we sought to create a platform that would help optimize efficiency for Real-World Evidence (RWE) generation, market access, and HEOR-related activities.
Here is a summary of the research report in plain language:
Navigating the world of medication options for Parkinson’s Disease Psychosis (PDP) can be challenging, especially for older patients. The study sheds light on this issue, focusing on the effects of different antipsychotic medications on Long-Term Care Admissions (LTCA). This blog delves into the details of this crucial research.
The Study: A Closer Look
The study used a comprehensive US Medicare sample, including Medical claims and Pharmacy claims data spanning from 2013 to 2019. The primary aim was to compare the long-term care admission rates among patients aged 65 or older with Parkinson’s Disease Psychosis (PDP). The focus was on those initiated on Pimavanserin – the only FDA-approved Atypical Antipsychotic for Parkinson’s Disease Psychosis (PDP) – and other Atypical Antipsychotics, notably Quetiapine, which is often used off-label. The study suggested that starting Pimavanserin early may delay as well as reduce Long-Term Care Admissions (LTCA) among Medicare beneficiaries with Parkinson’s Disease Psychosis (PDP) compared to Quetiapine.
Methodology: Matching for Accuracy
To ensure a fair comparison, researchers meticulously matched individuals based on 31 different factors, including age, sex, race, region, and various comorbid health conditions. This approach resulted in two evenly matched groups, each comprising 842 patients, one treated with Pimavanserin and the other with Quetiapine.
Findings: A Comparative Analysis
The results were eye-opening. Patients treated with Pimavanserin displayed significantly lower rates of all-cause Long-Term Care Admissions (LTCA) (23.2% vs. 33.8%) and Skilled Nursing Facilities Stays (20.2% vs. 31.4%) compared to those on Quetiapine. The hazard ratios were equally telling, indicating a 22% lower risk of Skilled Nursing Facilities Stays and a 20% lower risk for overall Long-Term Care Admission (LTCA) for patients on Pimavanserin compared to Quetiapine.
We are very proud to announce that the scientific manuscript of this study, sponsored by Acadia Pharmaceuticals, has been published in the Journal of Comparative Effectiveness Research. The manuscript, along with references, can be accessed online here:
Implications: The Benefits of Pimavanserin
These findings suggest that starting Pimavanserin early in the treatment of Parkinson’s Disease Psychosis (PDP) could delay and reduce the need for Long-Term Care among Medicare beneficiaries. This is a significant insight, considering the physical, emotional, and financial burdens associated with Long-Term Care. The study also found that the results for Pimavanserin versus other Atypical Antipsychotics were similar to those observed in the Pimavanserin versus Quetiapine comparison, further bolstering the potential benefits of Pimavanserin in managing Parkinson’s Disease Psychosis (PDP).
Final Thoughts: A Step Forward in Parkinson’s Disease Psychosis (PDP) Management
This study is a milestone in understanding the impact of different antipsychotics on the Long-Term Care needs of older Parkinson’s Disease Psychosis (PDP) patients. It highlights the importance of choosing the right medication, not only for symptom management but also for reducing the likelihood of Long-Term Care Admissions (LTCA). For patients, caregivers, and healthcare professionals, these insights are invaluable in making informed decisions about Parkinson’s Disease Psychosis (PDP) treatment.
As we continue to explore the complexities of Parkinson’s Disease Psychosis (PDP) and its management, studies like this offer hope and guidance, paving the way for improved patient care and quality of life.